Form 4: Apellis Pharmaceuticals Director Sinclair A. Dunlop Reports Stock Sales

Director Sinclair A. Dunlop reports sales of Apellis Pharmaceuticals (APLS) stock held directly and indirectly through Epidarex Capital I LP and MASA.

Summary

• On June 21, 2024, Sinclair A. Dunlop, a director of Apellis Pharmaceuticals, reported the sale of common stock.
• 35,305 shares were sold at a weighted average price of $39.22, and 1,695 shares were sold at a weighted average price of $39.63.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on March 2, 2024.
• Following the transactions, Dunlop directly owns 133,518 shares and indirectly owns 136,998 shares through Epidarex Capital I, LP and 31,855 shares through MASA.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by a company director. The sentiment is neutral as it simply reports transactions without expressing any positive or negative outlook on the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence by the director, although the sales were conducted under a pre-arranged trading plan.

Key Dates